Kornimate/medical-research-clean huggingface dataset:
evaluation of impacts of access to credit and loan size for microcredit clients in south africa

Conditions: Mental Health; Depression; Stress

Summary: this study involves randomization of individuals who were initially rejected from a micro-lending organization in south africa. subjects were placed into two arms: (1) not receiving a loan; (2) being reconsidered for a "second look." of those in the second arm, 53% were then selected by the organization's loan officers to receive a standard loan for first-time borrowers. mental health and financial data were collected at one timepoint: approximately 6-12 months after the subjects first applied for the loan.


Eligibility criteria:
inclusion criteria: * subjects were recruited from those who had been rejected from a lending organization for non-fraudulent or non-overindebtness reasons. exclusion criteria: * none.

Keywords: depression stress microcredit poverty south africa
ablation of inappropriate sinus tachycardia

Conditions: Inappropriate Sinus Tachycardia

Summary: hypothesis- radiofrequency ablation, targeting the sympathetic input of the sinus node identified by 20hz stimulation at the junction of the superior vena cava and the right atrium, will effectively reduce sinus rate acutely and will reduce palpitations due to inappropriate sinus tachycardia without the need for pacemaker implantation due to sinus node dysfunction post ablation.

inappropriate sinus tachycardia syndrome describes a condition in which a patient's heart rate is intermittently (or persistently) higher than expected for the physiological circumstances, with ecg appearance indistinguishable from normal sinus rhythm, after the exclusion of medical conditions causing sinus tachycardia. hypothesis- radiofrequency ablation, targeting the sympathetic input of the sinus node identified by 20hz stimulation at the junction of the superior vena cava and the right atrium, will effectively reduce sinus rate acutely and will reduce palpitations due to inappropriate sinus tachycardia without the need for pacemaker implantation due to sinus node dysfunction post ablation.

Eligibility criteria:
inclusion criteria: 1. patients between the ages of 18 and 80 years old, who are scheduled for an ablation procedure for suspected inappropriate sinus tachycardia, with symptomatic palpitations during periods where documented electrogram recordings suggest sinus tachycardia (holter, event recorder, or 12 lead ecg). 2. sinus rate greater than 100 bpm with minimal physiologic challenge, or mean sinus rate during 24 hour holter more than 95bpm, or daytime resting heart rate more than 95bpm. 3. symptoms (or sinus rate) not explained by an alternative medical or electrophysiological diagnosis. 4. symptoms refractory to treatment with beta-blocker medication, or beta-blockers contra-indicated or not tolerated exclusion criteria: 1. children under 18 years of age (due to greater risk from exposure to x rays). 2. any medical condition significantly increasing the risk of extending the ablation procedure or of x ray exposure, including pregnancy. 3. significant orthostatic hypotension (due to need for rapid chronotropic response to fall in blood pressure) 4. an alternative cause for sinus tachycardia identified (e.g. hyperthyroidism or pheochromocytoma). 5. inability or unwillingness to provide informed consent.

Keywords: inappropriate sinus tachycardia inappropriate tachycardia sinus tachycardia palpitations fast heart rate
social motivation intervention for children with autism spectrum disorder: improving peer initiation

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to investigate whether a social initiation motivation intervention (simi) focused on training children with asd to initiate to peers during structured play activities will result in more frequent initiations to typically developing peers during free play. the simi approach under investigation uses behavioral strategies based in applied behavior analysis and pivotal response treatment to motivate children with asd to initiate to peers. children with asd will be randomly assigned to either the simi or a waiting list. treatment will be provided for 8 weeks in the context of a weekly social skills group.


Eligibility criteria:
inclusion criteria: 1. age 4.0 to 6.11 years; 2. diagnosis of autism spectrum disorder 3. without intellectual disability 4. stable community treatments four weeks before and throughout the trial. exclusion criteria: 1. diagnosed severe psychiatric or genetic disorder or medical problem; 2. severe disruptive behavior that would interfere with peer interactions

Keywords: pivotal response treatment applied behavior analysis peer initiation social skills group
sleep-wakefulness status in preterm infants

Conditions: Sleep

Summary: this study was conducted to compare the effectiveness of three stair positioning pillows and positioning materials on the sleep-wakefulness status of preterm infants.

it is known that newborns have similar brain activity in the intrauterine period and rem sleep activity, and they sleep more than adults and spend most of their sleep in the rem sleep period. therefore, sleep quality in the newborn period is directly related to healthy development. providing a developmentally supportive position in neonatal intensive care units (nicu) is necessary not only for neuromotor and musculoskeletal development, but also for physiological function and stability, thermal regulation, bone density, neurobehavioral organization, calmness and comfort, skin integrity, optimal musculoskeletal development, facilitation of sleep, growth and brain development. excessive noise in the nicu, prolonged bright lights, separation from the mother, frequent invasive procedures and pain experience are among the factors that disrupt, shorten and create stress in the sleep duration of preterm babies. it is very important to support the sleep of preterm babies in the nicu in order to improve their growth and development, especially their brain development. it is known that therapeutic positions, which are one of the individualized developmental care practices, are effective on sleep.this study was conducted to compare the effectiveness of three stair positioning pillows and positioning materials on the sleep-wakefulness status of preterm infants.

Eligibility criteria:
inclusion criteria: * preterm infants who were postmenstrual age ≥30 and ≤34, * had an appropriate weight for gestational age (aga), * were spontaneously breathing (extubated and not receiving any oxygen support), * had no history of previous intubation, routinely had caffeine in their diet, and * whose parents volunteered to participate in the study were included in the study. exclusion criteria: * preterm infants who were \ 34 years postmenstrual, * had bradycardia, * received an analgesic 4 hours before that could affect sleep, * had sepsis, * congenital anomalies, * intracranial hemorrhage, * hyperbilirubinemia, * hypoglycemia, * underwent surgery, * received any oxygen support, or were on mechanical ventilation were excluded from the study.

Keywords: preterm infants neonatal intensive care unit
study of abatacept versus placebo to assess the prevention of rheumatoid arthritis (ra) in adult patients

Conditions: Arthritis, Rheumatoid

Summary: the purpose of this study is to assess if abatacept given for six months will prevent rheumatoid arthritis (ra) in patients who are at risk for the development of ra in comparison to placebo. high risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-ccp2).


Eligibility criteria:
inclusion criteria: * diagnosis of undifferentiated arthritis * clinical synovitis of two or more joints * at least one but not more than three of the criteria for diagnosis of ra (1987). * no prior disease modifying anti-rheumatic drugs (dmards)/biologics. * duration of disease must be 18 months or less. * positive for antibodies against cyclic citrullinated peptides. exclusion criteria: * women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy. * active vasculitis of a major organ system. * severe or recurrent bacterial infection. * history of cancer in the last five years except certain skin cancers. * herpes zoster that resolved less than 2 months prior to enrollment
role of altered cd40-ligand gene transcription in systemic lupus erythematosus

Conditions: Lupus Erythematosus, Systemic

Summary: systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the united states. recently, several research laboratories have reported that a protein, named cd40-ligand (cd154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. expression of cd154 appears critical to the generation of antibodies that cause disease in lupus. blocking cd154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. we propose to study the regulation of cd154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.


Eligibility criteria:
inclusion: a diagnosis of systemic lupus erythematosus
single patient compassionate use / expanded access l-s-gboxin (lyophilized form of s-gboxin) for the treatment of diffuse midline glioma

Conditions: DIPG Brain Tumor; Diffuse Brainstem Glioma; H3 K27M; H3 K28M; GBM

Summary: f. 50y.o. 77kg, ds confirmed 18 nov. 2022 received treatment: 11 courses of tmz (240mg) radiotherapy 30 courses of 1.8gr (total 54 gr, tmz 140 mg on rt). bevacizumab intravenously -400 mg -0-14-28-42 (december-february 2023). severe side effects. the attending physician discontinued bevacizumab after 4 courses. in remission for 11 months. according to the results of the mri dated april 28, 2024, continued growth. neurological status is good. reflexes are not impaired. to date, treatment options have been exhausted. participation of the patient in clinical trials is impossible. as of april 2024, negative dynamics. the patient signed an informed consent agreement. information on taking l-s-gboxin (lyophilisate) as part of a compassionate program - explained. written consent of the attending physician for the patient's participation in the compassion program (triangle) with l-s-gboxi (lyophilisate) - received. (medical documentation will be available on clinicaltrials.gov within a month from the date of publication - patient's consent to publish the medical history and examination results has been obtained)

treatment plan оn days 1 to 3 of treatment, the patient will receive a sublingual form of the lyophilized form of l-s-gboxin at a dose of 5 mg/kg. if there is no toxicity, on days 4 to 14 the patient will receive a sublingual form of the lyophilized form of s-gboxin at a dose of 10 mg/kg. the first course of treatment is 14 days. on day 20, mri + pet-ct monitoring is carried out to assess the dynamics of tumor growth. based on the results of the examination plan, the attending physician and the main investigator make a decision on the continuation of treatment and the duration of the second course of therapy.

Eligibility criteria:
inclusion criteria: unacceptable for single patient exclusion criteria: * unacceptable cardiotoxicity * cerebrospinal fluid dissemination * systemic infection or viral disease, other associated symptoms that may jeopardize the patient's safety (at the discretion of the treating physician)

Keywords: s-gboxin s-gboxin (lyophilized form)
long term study of genotropin (somatropin) for short children born small for gestational age (sga)

Conditions: Short Stature Born Small for Gestational Age (SGA)

Summary: to assess the long-term safety of genotropin(somatropin) on small for gestational age (sga) without epiphyseal closing.


Eligibility criteria:
inclusion criteria: children with short stature due to sga who received treatment in the study genasg-0021-002. exclusion criteria: * children who have any chronic disease requiring treatment with steroid hormone that may affect growth promotion including estrogen, androgen, anabolic hormone, and corticosteroids (except those for external use), and have received the treatment. * children who have received radiotherapy or chemotherapy. * children who have serious cardiac disease, renal disease, or hepatic disease. * children who have diabetes mellitus with a manifestation of abnormal glucose metabolism. * children who have serious chronic disease. * children who have malignant tumor. * children who are allergic to m-cresol.

Keywords: genotropin(somatropin) sga short stature long-term safety
proposal of a score to detect the need for postoperative intensive care unit admission after bariatric surgery

Conditions: Bariatric Surgery Procedures

Summary: the purpose of this study is to propose a multi-dimensional score to predict those patients undergoing bariatric surgeries who will be in need for postoperative icu admission.

a multi-dimensional score of 7 risk factors was proposed which may help in identifying morbidly obese patients undergoing bariatric surgeries who will need admission to a critical care unit postoperatively for follow up.

Eligibility criteria:
inclusion criteria: * patients who have been operated upon for either laparoscopic gastric sleeve or laparoscopic gastric bypass during the period from january to june 2016. exclusion criteria: * patients were excluded in case of postoperative surgical complications, conversion to open surgery or in case of redo.

Keywords: morbid obesity bariatric surgery multi-dimensional score
comparison of the efficacy and safety of closone and clopidogrel with aspirin

Conditions: Coronary Artery Disease

Summary: the aim of this study is to prove non-inferiority of closone to the combination treatment of plavix with astrix.


Eligibility criteria:
inclusion criteria: * subjects under condition after post-percutaneous coronary artery intervention over twelve months * 20\~85 years old * willing to adhere to protocol requirements and sign a informed consent form exclusion criteria: * subject who did not undergo or failed stent implantation * subjects who took an anti-coagulant, anti-thrombotic regularly before the study, or plan to have continuous treatment during the study * subjects with a history of hypersensitivity to clopidogrel, aspirin * subjects with uncontrolled severe hypertension * subjects with high risk of hemorrhage like blood coagulation disorders :gastrointestinal bleeding, gross hematuria, intraocular bleeding, hemorrhagic stroke, intracranial hemorrhage * subjects with intractable arrhythmia, intracranial hemorrhage * subjects with severe cardiomyopathy (new york heart association(nyha) class ⅳ) * subjects with severe hepatopathy(ast and alt \> 10 times the upper limit of normal) * subjects who are pregnant, breastfeeding and not using medically acceptable birth control * subjects considered as unsuitable based on medical judgement by investigators
evaluation of vitrase as an adjuvant to increase absorption and dispersion of other injected anesthetics

Conditions: Pain

Summary: the purpose of this study is to evaluate vitrase as an adjuvant to increase absorption and dispersion of other injected anesthetics


Eligibility criteria:
inclusion criteria: * scheduled for an ophthalmic surgical procedure exclusion criteria: * known allergy to bee venom

Keywords: adjuvants, anesthesia hyaluronate lyase
evaluation of emergency computed tomography in suspected renal colic. this is an observational retrospective study aimed to evaluate emergency computed tomography in patients at the emergency department in helsingborg, sweden, with suspected acute renal colic.

Conditions: Kidney Stone

Summary: the goal of this observational study is to learn more about diagnostics in patients with suspected acute renal colic at the emergency department. the main questions it aims to answer are: * how many patients with symtoms of urolithiasis have a stone in the urinary tract at the emergency computed tomography (ct) * location and size of the stones. * evaluate time to intervention and closure and if this has changed due to emergency ct. participants are patients with symtoms of suspected acute renal colic at the emergency department in helsingborg with an emergency ct within 24 hours.

since october 2022 the national guidelines in sweden recommend emergency ct for patients with suspected acute renal colic at the emergency department. in may 2023 the department of urology implemented this new regime with emergency ct for these patients in collaboration with the department of emergency and the department of radiology. this study aims to evaluate the first year (may 2023 to may 2024) with this new regime. data regarding these patients where gathered regarding decriptive data, data regarding the stone, interventions and follow up. the investigators aim to compare the data with data from a soon to be published (scandinavian journal of urology) article evaluating the situation regarding these patients during one year 2018-2019.

Eligibility criteria:
inclusion criteria: * patient at the emergency department with suspected acute renal colic and an emergency ct within 24 hours 10 may 2023 to 9 may 2024. exclusion criteria: * none

Keywords: neprolithiasis kidney diseases urologic disease urinary calculi kidney calculi renal colic pain computed tomography urogenital disease
effectiveness and safety of platelet-rich plasma and topical 5% minoxidil combination in male androgenetic alopecia

Conditions: Androgenetic Alopecia

Summary: the goal of this clinical trial is to learn about the effectiveness and safety of platelet-rich plasma (prp) and topical 5% minoxidil combination therapy compared with topical 5% minoxidil monotherapy in male androgenetic alopecia. the main questions it aims to answer are: * is there a difference in average change of hair density between groups that were given a combination of prp injection and topical minoxidil compared to topical minoxidil as monotherapy? * is there a difference in average change of hair thickness between groups that were given a combination of prp and topical minoxidil compared to topical minoxidil as monotherapy? * are there any differences in side effects between groups that were given combination of prp and topical minoxidil compared to topical minoxidil as monotherapy?

the trial will be held for three months in jakarta, indonesia. participants are required to undergo hair examinations every 4 weeks, for a total of 4 visits. researchers will compare groups that were given a combination of prp and topical minoxidil compared to topical minoxidil alone as a control group. hair density, hair thickness, and overall side effects of treatment will be measured at each visit.

Eligibility criteria:
inclusion criteria: * men between 18 and 50 years old * diagnosed with grade iii-vi androgenetic alopecia based on hamilton-norwood scale * willing to be the research subject and make regular follow-up visits. exclusion criteria: * conditions of baldness other than androgenetic alopecia based on anamnesis and physical examination, namely telogen effluvium, alopecia areata, trichotillomania, syphilis secondary, systemic lupus erythematosus, alopecia due to chemotherapy, autoimmune, or malignancy. * taking oral medications or vitamins that aim to increase the amount of hair in the last 1 month. * using topical medication that aims to increase the amount of hair in the last 2 weeks. * suffering from active bacterial, viral, or fungal infections of the scalp. * underwent cosmetic procedures for androgenetic alopecia treatment (such as prp injections, laser procedures, or microneedle) within the last 3 months prior to the study. * history of keloids. * history of blood clotting disorders.

Keywords: platelet-rich plasma topical minoxidil combination therapy
pharmacokinetics and pharmacodynamics of high versus standard dose rifampicin in patients with pulmonary tuberculosis

Conditions: Tuberculosis

Summary: in this phase ii clinical trial, the pharmacokinetics, safety and (short-term) efficacy of higher than standard doses rifampicin will be studied during the intensive phase of tuberculosis (tb) treatment. patients enrolled in this study will either get the standard tb regimen (including 600 mg rifampicin; first study arm), or 900 mg rifampicin plus isoniazid, ethambutol and pyrazinamide in standard dosages (second study arm), or 1200 mg rifampicin plus the other drugs in standard dosages (third study arm). all patients will get the standard tb regimen during the continuation phase of treatment.


Eligibility criteria:
inclusion criteria: * participant has a newly diagnosed pulmonary tuberculosis, confirmed by a positive smear of at least two sputum specimens with zn staining. * participant is willing to be tested for hiv. * participant is at least 18, but not more than 65 years of age at the day of the first dosing of study medication. * participant is admitted to knth or kcmc during the intensive phase of tb treatment. * participant is able and willing to attend to knth or kcmc regularly during the continuation phase of tb treatment. * participant is able to understand and willing to sign the informed consent form prior to screening evaluations. * female participants should understand that it is important not to get pregnant during the study. they should agree on taking measures to prevent them from getting pregnant during the study. they should agree on taking measures to prevent them from getting pregnant, such as using a contraceptive device or barrier method. exclusion criteria: * participant has been treated with anti-tuberculosis drugs during the past three years. * participant's body weight is less than 50 kg. * participant has abnormal liver function test or serum creatinine (defined as levels higher than the upper limit of normal). * participant has a relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (i.e. chronic gastro-intestinal disease, diabetes mellitus, renal or hepatic disease, use of concomitant drugs that interfere with the pharmacokinetics of anti-tb drugs). * participant is on anti-retroviral treatment at inclusion. * participant has a cd4 count less than 350 cells/mm3. * participant has a karnofsky score of less than 40. * participant is pregnant or breastfeeding. * participant has a multi drug resistant (mdr)-tb for which another than the standard treatment regimen is needed.

Keywords: tuberculosis rifampicin pharmacokinetics pharmacodynamics